Quantitative Assays Reveal Cell Fusion at Minimal Levels of SARS-CoV-2 Spike Protein and Fusion-from-Without
S. A. Theuerkauf, A. Michels, V. Riechert, T. J. Maier, E. Flory, K. Cichutek, C. J. Buchholz
Abstract
Cell entry of the pandemic virus SARS-CoV-2 is mediated by its spike protein S. As main antigenic determinant, S protein is in focus of antibody-based prophylactic and therapeutic strategies. Besides particle-cell fusion, S mediates fusion between infected and uninfected cells resulting in syncytia formation. Here we present quantitative assay systems covering not only particle-cell and cell-cell fusion, but also demonstrating fusion-from-without (FFWO), the formation of syncytia induced by S-containing viral particles in absence of newly synthesized S protein. Based on complementation of split {beta}-galactosidase and virus-like-particles (VLPs) displaying S protein, this assay can be performed at BSL-1. All three assays provided readouts with a high dynamic range and signal-to-noise ratios covering several orders of magnitude. The data obtained confirm the enhancing effect of trypsin and overexpression of angiotensin-converting enzyme 2 (ACE2) on membrane fusion. Neutralizing antibodies as well as sera from convalescent patients inhibited particle-cell fusion with high efficiency. Cell-cell fusion, in contrast, was only moderately inhibited despite requiring much lower levels of S protein, which were below the detection limit of flow cytometry and Western blot. The data indicate that syncytia formation as a pathological consequence in tissues of Covid-19 patients can proceed at low levels of S protein and may not be effectively prevented by antibodies.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- A cellular assay for spike/ACE2 fusion: quantification of fusion-inhibitory antibodies after COVID-19 and vaccination
F. Abdul, P. Ribaux, … O. Preynat-Seauve·bioRxiv·Jun 9, 2022
- SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in the requirements for receptor expression and proteolytic activation
B. F. Hörnich, A. K. Grosskopf, … A. S. Hahn·Journal of VirologyPeer-reviewed·Apr 12, 2021
- The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections
F. Musarrat, V. Chouljenko, … K. Kousoulas·bioRxiv·Apr 24, 2020
- Expression and fusogenic activity of SARS CoV-2 Spike protein displayed in the HSV-1 Virion.
Prashant J. Desai·bioRxiv·Nov 28, 2023
- Unveiling the Complete Spectrum of SARS-CoV-2 Fusion Stages by In Situ Cryo-ET
Caner Akıl, Jialu Xu, … Peijun Zhang·Nature CommunicationsPeer-reviewed·Jun 3, 2025
- Impaired potency of neutralizing antibodies against cell-cell fusion mediated by SARS-CoV-2